{"id":31,"date":"2024-11-20T17:15:05","date_gmt":"2024-11-20T17:15:05","guid":{"rendered":"https:\/\/www.vimizim.com\/en-us\/?page_id=31"},"modified":"2026-05-11T14:45:05","modified_gmt":"2026-05-11T14:45:05","slug":"how-vimizim-can-help","status":"publish","type":"page","link":"https:\/\/www.vimizim.com\/en-us\/how-vimizim-can-help\/","title":{"rendered":"How VIMIZIM Can Help"},"content":{"rendered":"<div id=\"acf-block-674df815d803b\" class=\"page-header\">         \n            \n        <div class=\"header-image\" style=\"background-image: url(https:\/\/www.vimizim.com\/en-us\/wp-content\/uploads\/sites\/2\/2024\/12\/about_hero.png?v=0.58)\"><\/div>\n     \n    <div class=\"header-content\">\n                    <h1>VIMIZIM<sup>\u00ae<\/sup> (elosulfase alfa) works to help with deficient enzyme activity<\/h1>\n            <\/div>\n<\/div>\n\n<div id=\"acf-block-673f60fdb5c3d\" class=\"block split-content equal-bias\" data-muted-autoplay=\"false\">\n\t<div class=\"wrapper\">\n\t\t<div class=\"inner-wrapper\">\n\t\t                                                                <div class=\"content-block first-block\">\n                                                                                                <h2>How VIMIZIM\u00a0works<\/h2>\n<p><strong>VIMIZIM\u00a0works at the cellular level in your body<\/strong><\/p>\n<p>People born with Morquio A are missing, or don\u2019t have enough of, an enzyme known as\u00a0<em>N<\/em>\u2010acetylgalactosamine\u20106\u2010sulfatase, or GALNS, which breaks down and recycles glycosaminoglycans, or GAGs, a type of cellular waste. VIMIZIM can help replace the deficient GALNS to help restore some cell function.<\/p>\n                                                                                    <\/div>\n                    \n                                            <div class=\"content-block second-block\">\n                                                                                                                                                                                                                                                                                    \n                                    \n                                    \n                                    \n                                    <figure>\n                                        <div class=\"image\">\n                                                                                            <img decoding=\"async\" class=\"\" src=\"https:\/\/www.vimizim.com\/en-us\/wp-content\/uploads\/sites\/2\/2024\/11\/Group-6-Copy.png?v=0.58\" alt=\"\" \/>                                                                                    <\/div>\n                                                                            <\/figure>\n                                                                                    <\/div>\n                                                \t\t<\/div>\n\t<\/div>\n<\/div>\n\n<div id=\"acf-block-673f60fdb5ecb\" class=\"block cards cards-3-col\">\n\t<div class=\"wrapper\">\n\t\t<div class=\"inner-wrapper\">\n\t\t\t<div class=\"cards-title\">\n\t\t\t    \t\t\t\t\t\t\t<\/div>\n\t\t\t<div class=\"cards-wrapper\">\n\t\t\t    \n<div id=\"acf-block-673f60fdb64be\" class=\"card\" data-muted-autoplay=\"false\">\n    \t    \n\n                    <img decoding=\"async\" class=\"card-image\" src=\"https:\/\/www.vimizim.com\/en-us\/wp-content\/uploads\/sites\/2\/2024\/11\/Group-36-1.png?v=0.58\" alt=\"\" \/>        \n\t    <div class=\"card-content\">\n                \n                                                                                                            <p>In people with Morquio A, GAGs build up in cells throughout the tissues and organs of the body, potentially causing serious problems.<\/p>\n                                                                                    <\/div>\n<\/div>\n\n<div id=\"acf-block-673f60fdb6529\" class=\"card\" data-muted-autoplay=\"false\">\n    \t    \n\n                    <img decoding=\"async\" class=\"card-image\" src=\"https:\/\/www.vimizim.com\/en-us\/wp-content\/uploads\/sites\/2\/2024\/11\/Group-39-3.png?v=0.58\" alt=\"\" \/>        \n\t    <div class=\"card-content\">\n                \n                                                                                                            <p>A weekly infusion of VIMIZIM may help replace the deficient GALNS enzyme your body needs to help reduce the buildup of certain GAGs.<\/p>\n                                                                                    <\/div>\n<\/div>\n\n<div id=\"acf-block-673f60fdb658a\" class=\"card\" data-muted-autoplay=\"false\">\n    \t    \n\n                    <img decoding=\"async\" class=\"card-image\" src=\"https:\/\/www.vimizim.com\/en-us\/wp-content\/uploads\/sites\/2\/2024\/11\/Group-41-2.png?v=0.58\" alt=\"\" \/>        \n\t    <div class=\"card-content\">\n                \n                                                                                                            <p>Receiving VIMIZIM every week may help people with Morquio A reduce the buildup of certain GAGs.<\/p>\n                                                                                    <\/div>\n<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n<div id=\"acf-block-673f65f3cd2b1\" class=\"block wrapped-content block-tight-bottom\">\n    <div class=\"wrapper\">\n        <div class=\"inner-wrapper\">\n                \n<div id=\"acf-block-673f65f3cd427\" class=\"block-wysiwyg\">\n            <h2>VIMIZIM improved endurance with long-lasting benefits<\/h2>\n    <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\n<div id=\"acf-block-673f65f3ce063\" class=\"block tabbed-content block-tight-top\">\n\t    <div class=\"wrapper\">\n\t\t<div class=\"inner-wrapper\">\n\t\t                                                                                        <ul class=\"tabs\">\n                                                                                                                            <li><a href=\"#acf-block-673f65f3ce063_0\">IMPROVED ENDURANCE\n<\/a><\/li>\n                                                                                                                                                            <li><a href=\"#acf-block-673f65f3ce063_1\">LONG-LASTING BENEFITS\n<\/a><\/li>\n                                                                                    <\/ul>\n                                                                                                                                                <div class=\"box\">\n                                                                                            <div class=\"tab-content\" id=\"acf-block-673f65f3ce063_0\" style=\"display:none;\">\n                                                                                                                                                                                                                                                                                                                        <div class=\"block split-content\">\n                                                    <div class=\"wrapper\">\n\t\t                                                <div class=\"inner-wrapper\">\n                                                                                                                            <div class=\"content-block\">\n                                                                                                                                                                                                                        <h5>VIMIZIM improved endurance at 6 months<\/h5>\n<p>In a 24-week clinical trial, people who received VIMIZIM infusions every week improved their endurance as measured by the 6-minute walk test (6MWT). The number of people included in the study was intentionally chosen to see the effect of VIMIZIM on the 6MWT and the 3-minute stair climbing test. Other tests or measures were assessed to see if they might be valid for future study.<\/p>\n<ul>\n<li>This graph shows that by the end of a 24-week trial, people who received VIMIZIM once a week walked an average of\u00a023.9% farther\u00a0than at baseline<\/li>\n<li>People who received VIMIZIM every other week did not show much improvement, and their results were similar to the people who received a placebo<\/li>\n<\/ul>\n<h4>Maintaining weekly infusions is essential to making the most out of your treatment.<\/h4>\n                                                                                                                                                                                                            <\/div>\n                                                            \n                                                                                                                            <div class=\"content-block\">\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \n                                                                            \n                                                                            \n                                                                            \n                                                                            <figure>\n                                                                                <div class=\"image\">\n                                                                                                                                                                            <img decoding=\"async\" class=\"\" src=\"https:\/\/www.vimizim.com\/en-us\/wp-content\/uploads\/sites\/2\/2026\/03\/Endurance.png?v=0.58\" alt=\"\" \/>                                                                                                                                                                    <\/div>\n                                                                                                                                                            <\/figure>\n                                                                                                                                                                                                                                                                                                <p><sup>a<\/sup><small>A baseline is a measurement of a person\u2019s performance before they begin treatment in a clinical trial. To participate in the clinical trial for VIMIZIM, people had to be able to walk more than 30 meters but less than 325 meters in 6 minutes.<\/small><br \/>\n<sup>b<\/sup><small>A placebo is a harmless substance that does not contain any medicine.<\/small><\/p>\n<h4>Patients in the VIMIZIM once-weekly treatment arm saw a 23.9% mean improvement in 6MWT over baseline.<\/h4>\n<p>&nbsp;<\/p>\n                                                                                                                                                                                                            <\/div>\n                                                                                                                    <\/div>\n                                                    <\/div>\n                                                <\/div>\n                                                                                                                                                                                                                                <h5>Talk to your doctor about your individual VIMIZIM treatment goals<\/h5>\n<p>Knowing what to expect from your treatment with VIMIZIM can help you know what success looks like. For some people, this might mean that the impact of Morquio A becomes stabilized. Work with your doctor to develop treatment goals that are right for you.<\/p>\n<h5>Side effects<\/h5>\n<p>The most common side effects reported during VIMIZIM infusions included fever, vomiting, headache, nausea, abdominal pain, chills, and fatigue. These are not all of the possible side effects with VIMIZIM. Talk to your doctor if you have any symptoms that bother you or that do not go away.<\/p>\n<p>Serious and severe reactions were associated with VIMIZIM, including hypersensitivity reactions as well as life-threatening allergic reactions (anaphylaxis), risk of acute respiratory complications, and spinal or cervical cord compression.<\/p>\n<ul>\n<li>In clinical trials, 18.7% of patients treated with VIMIZIM experienced hypersensitivity reactions and 7.7% experienced anaphylaxis<\/li>\n<\/ul>\n<p><strong>Call your doctor for medical advice about side effects. You may report side effects to BioMarin Pharmaceutical Inc. at 1-866-906-6100, or FDA at 1-800-FDA-1088 or go to\u00a0<a href=\"http:\/\/www.fda.gov\/medwatch\" target=\"_blank\" rel=\"noopener\">www.fda.gov\/medwatch<\/a>.<\/strong><\/p>\n                                                                                                                                                        <\/div>\n                                                                                                                            <div class=\"tab-content\" id=\"acf-block-673f65f3ce063_1\" style=\"display:none;\">\n                                                                                                                                                                                                                        <h5>VIMIZIM may provide long-lasting benefits<\/h5>\n<p>A 120-week extension study showed that the benefits of VIMIZIM can be maintained over the long term and are consistent with the results of the primary study.<\/p>\n<p>In the 2-year extension study (MOR-005), all patients transitioned over time to receive VIMIZIM as a once-weekly treatment. The results of the treated patient group could not be compared to placebo since the study did not include a placebo group.<\/p>\n                                                                                                                                                                                                                                                                                                                                    <ul class=\"icon-list top\">\n                                                                                                                                                                                                                                            <li>\n                                                                <div class=\"icon\" style=\"background-image: url(https:\/\/www.vimizim.com\/en-us\/wp-content\/uploads\/sites\/2\/2024\/12\/IncreasedEndurance-100x100.png);\"><\/div>\n                                                                <div>\n                                                                    <h5>Improved endurance<\/h5>\n<p>Results from the long-term extension study showed a 32.9-meter mean increase in the 6-minute walk test (6MWT) compared to baseline.<\/p>\n<p>&nbsp;<\/p>\n                                                                <\/div>\n                                                            <\/li>\n                                                                                                                                                                                                                                            <li>\n                                                                <div class=\"icon\" style=\"background-image: url(https:\/\/www.vimizim.com\/en-us\/wp-content\/uploads\/sites\/2\/2024\/12\/Page-1-11-100x100.png);\"><\/div>\n                                                                <div>\n                                                                    <h5>Helped lungs work better<\/h5>\n<p>Breathing function as measured by pulmonary function tests improved for patients in the long-term extension study compared to baseline.<\/p>\n<p>There was a\u00a0<strong>9.2% mean increase in FVC<\/strong> compared with baseline.<\/p>\n<p>There was an\u00a0<strong>8.8% mean increase in FEV<sub>1<\/sub><\/strong>\u00a0 compared with baseline.<\/p>\n                                                                <\/div>\n                                                            <\/li>\n                                                                                                            <\/ul>\n                                                                                                                                                                                                                                                                                <p><small><strong>FEV<sub>1<\/sub>,\u00a0<\/strong>maximum volume of air that can be forcibly blown out in 1 second;\u00a0<strong>FVC<\/strong>, volume of air that can forcibly be exhaled from the lungs after taking the deepest breath possible.<\/small><\/p>\n<h5>Side effects<\/h5>\n<p>The most common side effects reported during VIMIZIM infusions included fever, vomiting, headache, nausea, abdominal pain, chills, and fatigue. These are not all of the possible side effects with VIMIZIM. Talk to your doctor if you have any symptoms that bother you or that do not go away.<\/p>\n<p>Serious and severe reactions were associated with VIMIZIM, including hypersensitivity reactions as well as life-threatening allergic reactions (anaphylaxis).<\/p>\n<ul>\n<li>In clinical trials, 18.7% of patients treated with VIMIZIM experienced hypersensitivity reactions and 7.7% experienced anaphylaxis<\/li>\n<\/ul>\n<p><strong>Call your doctor for medical advice about side effects. You may report side effects to BioMarin Pharmaceutical Inc. at 1-866-906-6100, or FDA at 1-800-FDA-1088 or go to\u00a0<a href=\"http:\/\/www.fda.gov\/medwatch\" target=\"_blank\" rel=\"noopener\">www.fda.gov\/medwatch<\/a>.<\/strong><\/p>\n<p>&nbsp;<\/p>\n                                                                                                                                                        <\/div>\n                                                                                    <\/div>\n                                    \t\t\t\t\t\t\t\t<\/div>\n\t<\/div>\n<\/div>\n\n<div id=\"acf-block-6743bef46c61a\" class=\"block wrapped-content\">\n    <div class=\"wrapper\">\n        <div class=\"inner-wrapper\">\n                \n<div id=\"acf-block-6743bef46c77e\" class=\"block-wysiwyg\">\n            <p style=\"text-align: right\"><a href=\"https:\/\/www.vimizim.com\/en-us\/side-effects\/\">Learn more about the possible side effects of VIMIZIM &gt;<\/a><\/p>\n    <\/div>\n        <\/div>\n    <\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-31","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>How VIMIZIM Can Help - BioMarin Vimizim Patient EN-US<\/title>\n<meta name=\"description\" content=\"A weekly infusion of VIMIZIM (elosulfase alfa) replaces the deficient GALNS enzyme activity your body needs to break down the buildup of Gags. View important safety information, including risk of anaphylaxis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.vimizim.com\/en-us\/how-vimizim-can-help\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How VIMIZIM can help\" \/>\n<meta property=\"og:description\" content=\"A weekly infusion of VIMIZIM (elosulfase alfa) replaces the deficient GALNS enzyme activity your body needs to break down the buildup of Gags. View important safety information, including risk of anaphylaxis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.vimizim.com\/en-us\/how-vimizim-can-help\/\" \/>\n<meta property=\"og:site_name\" content=\"BioMarin Vimizim Patient EN-US\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-11T14:45:05+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.vimizim.com\\\/en-us\\\/how-vimizim-can-help\\\/\",\"url\":\"https:\\\/\\\/www.vimizim.com\\\/en-us\\\/how-vimizim-can-help\\\/\",\"name\":\"How VIMIZIM Can Help - BioMarin Vimizim Patient EN-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.vimizim.com\\\/en-us\\\/#website\"},\"datePublished\":\"2024-11-20T17:15:05+00:00\",\"dateModified\":\"2026-05-11T14:45:05+00:00\",\"description\":\"A weekly infusion of VIMIZIM (elosulfase alfa) replaces the deficient GALNS enzyme activity your body needs to break down the buildup of Gags. View important safety information, including risk of anaphylaxis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.vimizim.com\\\/en-us\\\/how-vimizim-can-help\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.vimizim.com\\\/en-us\\\/how-vimizim-can-help\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.vimizim.com\\\/en-us\\\/how-vimizim-can-help\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.vimizim.com\\\/en-us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How VIMIZIM Can Help\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.vimizim.com\\\/en-us\\\/#website\",\"url\":\"https:\\\/\\\/www.vimizim.com\\\/en-us\\\/\",\"name\":\"BioMarin Vimizim Patient EN-US\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.vimizim.com\\\/en-us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"How VIMIZIM Can Help - BioMarin Vimizim Patient EN-US","description":"A weekly infusion of VIMIZIM (elosulfase alfa) replaces the deficient GALNS enzyme activity your body needs to break down the buildup of Gags. View important safety information, including risk of anaphylaxis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.vimizim.com\/en-us\/how-vimizim-can-help\/","og_locale":"en_US","og_type":"article","og_title":"How VIMIZIM can help","og_description":"A weekly infusion of VIMIZIM (elosulfase alfa) replaces the deficient GALNS enzyme activity your body needs to break down the buildup of Gags. View important safety information, including risk of anaphylaxis.","og_url":"https:\/\/www.vimizim.com\/en-us\/how-vimizim-can-help\/","og_site_name":"BioMarin Vimizim Patient EN-US","article_modified_time":"2026-05-11T14:45:05+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.vimizim.com\/en-us\/how-vimizim-can-help\/","url":"https:\/\/www.vimizim.com\/en-us\/how-vimizim-can-help\/","name":"How VIMIZIM Can Help - BioMarin Vimizim Patient EN-US","isPartOf":{"@id":"https:\/\/www.vimizim.com\/en-us\/#website"},"datePublished":"2024-11-20T17:15:05+00:00","dateModified":"2026-05-11T14:45:05+00:00","description":"A weekly infusion of VIMIZIM (elosulfase alfa) replaces the deficient GALNS enzyme activity your body needs to break down the buildup of Gags. View important safety information, including risk of anaphylaxis.","breadcrumb":{"@id":"https:\/\/www.vimizim.com\/en-us\/how-vimizim-can-help\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.vimizim.com\/en-us\/how-vimizim-can-help\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.vimizim.com\/en-us\/how-vimizim-can-help\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.vimizim.com\/en-us\/"},{"@type":"ListItem","position":2,"name":"How VIMIZIM Can Help"}]},{"@type":"WebSite","@id":"https:\/\/www.vimizim.com\/en-us\/#website","url":"https:\/\/www.vimizim.com\/en-us\/","name":"BioMarin Vimizim Patient EN-US","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.vimizim.com\/en-us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.vimizim.com\/en-us\/wp-json\/wp\/v2\/pages\/31","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.vimizim.com\/en-us\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.vimizim.com\/en-us\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.vimizim.com\/en-us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.vimizim.com\/en-us\/wp-json\/wp\/v2\/comments?post=31"}],"version-history":[{"count":69,"href":"https:\/\/www.vimizim.com\/en-us\/wp-json\/wp\/v2\/pages\/31\/revisions"}],"predecessor-version":[{"id":907,"href":"https:\/\/www.vimizim.com\/en-us\/wp-json\/wp\/v2\/pages\/31\/revisions\/907"}],"wp:attachment":[{"href":"https:\/\/www.vimizim.com\/en-us\/wp-json\/wp\/v2\/media?parent=31"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}